Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.57 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.55 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.55 |
| ▸ | HTR2B | P41595 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | CA7 | P43166 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1063365 | 0.96 | MEN1 (0.66) | MEN1KMT2AGRIN2BHTTCA12 | |
| SCHEMBL14337827 | 0.93 | MEN1 (0.66) | MEN1KMT2ACHRM2GRIN2BCYP2C9 | |
| SCHEMBL14337824 | 0.93 | MEN1 (0.63) | MEN1KMT2AGRIN2BHTTCA12 | |
| SCHEMBL5203675 | 0.93 | MEN1 (0.63) | MEN1KMT2AGRIN2BHTTCA12 | |
| SCHEMBL14337831 | 0.92 | MEN1 (0.62) | MEN1KMT2AGRIN2BHTTCA12 | |
| SCHEMBL1083550 | 0.91 | MEN1 (0.60) | MEN1KMT2ACHRM2GRIN2BCYP2C9 | |
| SCHEMBL20883160 | 0.91 | MEN1 (0.63) | MEN1KMT2ACHRM2GRIN2BHTT | |
| SCHEMBL5201937 | 0.91 | MEN1 (0.61) | MEN1KMT2AGRIN2BHTTCA12 | |
| SCHEMBL1059651 | 0.90 | MEN1 (0.60) | MEN1KMT2AGRIN2BCYP2C9CYP2C19 | |
| SCHEMBL5353806 | 0.88 | MEN1 (0.60) | MEN1KMT2ACHRM2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110008289-A1 | HYPERGLYCOSYLATED POLYPEPTIDE VARIANTS AND METHODS OF USE | ALIOS BIOPHARMA, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-20100099851-A1 | SYNTHETIC HYPERGLYCOSYLATED, PROTEASE-RESISTANT POLYPEPTIDE VARIANTS, ORAL FORMULATIONS AND METHODS OF USING THE SAME | ALIOS BIOPHARMA, INC. (US) | 2010-04-22 | — | — | US | disclosed |
| US-7597884-B2 | Hyperglycosylated polypeptide variants and methods of use | ALIOS BIOPHARMA, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| EP-2093235-A1 | Hyperglycosylated variants of interferon alfacon-1 | Alios Biopharma Inc. (US) | 2009-08-26 | — | — | EP | disclosed |
| EP-1789074-A4 | SYNTHETIC HYPERGLYCOSYLATED, PROTEASE-RESISTANT POLYPEPTIDE VARIANTS, ORAL FORMULATIONS AND METHODS OF USING THE SAME | ALIOS BIOPHARMA INC (US) | 2009-08-12 | — | — | EP | disclosed |
| CN-101102787-A | Synthetic hyperglycosylated, and hyperglycosylated protease-resistant polypeptide variants, oral formulations and methods of using the same | ALIOS BIOPHARMA INC (US) | 2008-01-09 | — | — | CN | disclosed |
| EP-1789074-A2 | SYNTHETIC HYPERGLYCOSYLATED, PROTEASE-RESISTANT POLYPEPTIDE VARIANTS, ORAL FORMULATIONS AND METHODS OF USING THE SAME | Alios Biopharma Inc. (US) | 2007-05-30 | — | — | EP | disclosed |
| US-7189739-B2 | Compounds and methods to treat cardiac failure and other disorders | SCIOS, INC. (US) | 2007-03-13 | — | — | US | disclosed |
| US-7189739-B2 | Compounds and methods to treat cardiac failure and other disorders | SCIOS, INC. (US) | 2007-03-13 | — | — | US | disclosed |
| US-20060204473-A1 | Synthetic hyperglycosylated, and hyperglycosylated protease-resistant polypeptide variants, oral formulations and methods of using the same | ALIOS BIOPHARMA, INC. | 2006-09-14 | — | — | US | disclosed |
| US-20060182716-A1 | Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same | ALIOS BIOPHARMA, INC. | 2006-08-17 | — | — | US | disclosed |
| WO-2006020580-A2 | SYNTHETIC HYPERGLYCOSYLATED, PROTEASE-RESISTANT POLYPEPTIDE VARIANTS, ORAL FORMULATIONS AND METHODS OF USING THE SAME | ALIOS BIOPHARMA INC. (US) | 2006-02-23 | — | — | WO | disclosed |
| WO-2005110455-A2 | COMBINATION THERAPY FOR TREATING HEPATITIS VIRUS INFECTION | INTERMUNE, INC. (US) | 2005-11-24 | — | — | WO | disclosed |
| WO-2004105684-A2 | COMBINATION THERAPY FOR PROLIFERATIVE DISORDERS | INTERMUNE, INC. (US) | 2004-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099851-A1 | SYNTHETIC HYPERGLYCOSYLATED, PROTEASE-RESISTANT POLYPEPTIDE VARIANTS, ORAL FORMULATIONS AND METHODS OF USING THE SAME | IFNAR1, IDE, CTSC | MEN1 3779/4885KMT2A 4519/4885CHRM2 3906/4885 |
| US-20110008289-A1 | HYPERGLYCOSYLATED POLYPEPTIDE VARIANTS AND METHODS OF USE | IFNAR1, EPOR, HBB | MEN1 3843/4885KMT2A 4668/4885CHRM2 4618/4885 |
| US-20060182716-A1 | Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same | IFNAR1, IDE, CTSC | MEN1 3779/4885KMT2A 4519/4885CHRM2 3906/4885 |
| US-20060204473-A1 | Synthetic hyperglycosylated, and hyperglycosylated protease-resistant polypeptide variants, oral formulations and methods of using the same | IFNAR1, EPOR, HBB | MEN1 3792/4885KMT2A 4560/4885CHRM2 4675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.